Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Daratumumab as maintenance therapy after autoSCT in patients with multiple myeloma

Azra Borogovac, MD, City of Hope, Duarte, CA, discusses the findings of a Phase II study (NCT03346135) investigating the safety and efficacy of administering daratumumab as maintenance therapy for patients with multiple myeloma who have received autologous stem cell transplantation (autoSCT). Dr Borogovac discusses the progression-free survival (PFS) observed and also covers the results of mass cytometry analysis conducted on patient samples during the study. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.